The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation

RhoJ: an emerging biomarker and target in cancer research and treatment

RhoJ is a Rho GTPase that belongs to the Cdc42 subfamily and has a molecular weight of approximately 21 kDa. It can activate the p21-activated kinase family either directly or indirectly, influencing the activity of various downstream effectors and playing a role in regulating the cytoskeleton, cell movement, and cell cycle. RhoJ's expression and activity are controlled by multiple upstream factors at different levels, including expression, subcellular localization, and activation. High RhoJ expression is generally associated with a poor prognosis for cancer patients and is mainly due to an increased number of tumor blood vessels and abnormal expression in malignant cells. RhoJ promotes tumor progression through several pathways, particularly in tumor angiogenesis and drug resistance. Clinical data also indicates that high RhoJ expression is closely linked to the pathological features of tumor malignancy. There are various cancer treatment methods that target RhoJ signaling, such as direct binding to inhibit the RhoJ effector pocket, inhibiting RhoJ expression, blocking RhoJ upstream and downstream signals, and indirectly inhibiting RhoJ's effect. RhoJ is an emerging cancer biomarker and a significant target for future cancer clinical research and drug development.

Characterization of ATF2 in Rel/NFκB oncogenesis reveals its role in the regulation of Ras signaling

The v-Rel oncoprotein is the acutely transforming member of the Rel/NFκB family of transcription factors. v-Rel transforms cells through the inappropriate activation and suppression of genes normally regulated by cellular Rel/NFκB family members. We have recently demonstrated that activation of Ha-Ras by v-Rel contributes to transformation. Characterization of AP-1 family members in v-Rel-mediated transformation revealed ectopic expression of ATF2 inhibited transformation by blocking Ha-Ras activity. This lack of Ha-Ras activity prevented downstream activation of the Raf-MEK-ERK pathway, a critical pathway for v-Rel-mediated transformation. Microarray analysis of cells treated with an inhibitor to the ERK pathway revealed a relatively small number of genes that are specifically regulated by ERK activity in cells expressing v-Rel. These studies suggest the main contribution of ERK activity is to temper the expression of genes in v-Rel transformed cells. The mechanism by which ATF2 regulates Ras-Raf-MEK-ERK signaling appears to be a context dependent event. The ectopic expression of ATF2 in cells that are not expressing v-Rel results in the activation of Ha-Ras. However, activation of downstream Raf-MEK-ERK signaling pathway is blocked, likely through the recruitment of inhibitory 14-3-3 proteins to c-Raf. These results suggest a diverse role for ATF2 in the regulation of the Ras-Raf-MEK-ERK pathway.

Rho GTPase activation assays

The Rho GTPase family of signaling proteins controls a wide range of highly dynamic cellular processes. Activation of Rho GTPases can be investigated and quantified in cell extracts using so-called pull-down assays. Proteins that bind specifically to the activated form of the Rho GTPase are used to capture it onto a bead support. Western blotting of the captured samples with specific antibodies then allows for quantification of the level of Rho GTPase activation in the sample. This unit describes the techniques for preparing the reagents required for assays of RhoA, Rac, and Cdc42 and gives practical tips for the successful application of the assay in a range of situations.